Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.

Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM.

Br J Haematol. 2012 Jan;156(1):89-98. doi: 10.1111/j.1365-2141.2011.08901.x. Epub 2011 Oct 21.

PMID:
22017452
2.

CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16852-7. doi: 10.1073/pnas.1007896107. Epub 2010 Sep 14.

3.

The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure.

Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J, de Klerk NH, Kees UR.

Br J Haematol. 2005 Nov;131(4):447-56.

PMID:
16281934
4.

CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG.

Integr Biol (Camb). 2015 Feb;7(2):237-49. doi: 10.1039/c4ib00221k.

5.

Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.

Goodman PA, Wood CM, Vassilev AO, Mao C, Uckun FM.

Leuk Lymphoma. 2003 Jun;44(6):1011-8.

PMID:
12854903
6.

TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group.

Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G.

Blood. 1998 Mar 1;91(5):1716-22.

7.

Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.

Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, Sensel M, Reaman GH, Gaynon PS.

Clin Cancer Res. 2000 Aug;6(8):3123-30.

8.

Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.

Hoffmann K, Firth MJ, Beesley AH, Freitas JR, Ford J, Senanayake S, de Klerk NH, Baker DL, Kees UR.

Br J Haematol. 2008 Mar;140(6):656-64. doi: 10.1111/j.1365-2141.2008.06981.x.

PMID:
18302714
9.

Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.

Gottardo NG, Hoffmann K, Beesley AH, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Baker DL, Kees UR.

Br J Haematol. 2007 May;137(4):319-28.

PMID:
17456054
11.
12.

Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.

Lemos JA, Defavery R, Scrideli CA, Tone LG.

Sao Paulo Med J. 2003 Mar 5;121(2):58-62. Epub 2003 Jul 14.

13.

Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group.

Beyermann B, Agthe AG, Adams HP, Seeger K, Linderkamp C, Goetze G, Ludwig WD, Henze G.

Blood. 1996 Feb 15;87(4):1532-8.

14.

Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia.

Te Kronnie G, Bicciato S, Franceschini L, Accordi B, Dellíorto MC, Rinaldi A, Pession A, Barisone E, Conter V, Locatelli F, Basso G.

Oncol Rep. 2006 Feb;15(2):341-6.

PMID:
16391852
15.

Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.

Moreno DA, Scrideli CA, Cortez MA, de Paula Queiroz R, Valera ET, da Silva Silveira V, Yunes JA, Brandalise SR, Tone LG.

Br J Haematol. 2010 Sep;150(6):665-73. doi: 10.1111/j.1365-2141.2010.08301.x.

PMID:
20636436
16.

Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.

Zhu YM, Foroni L, McQuaker IG, Papaioannou M, Haynes A, Russell HH.

Br J Cancer. 1999 Mar;79(7-8):1151-7.

17.

DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.

Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM, van Huffel C, Langerak AW, van der Velden VH, Reinders MJ, van Dongen JJ.

Leukemia. 2003 Jul;17(7):1324-32. Erratum in: Leukemia. 2004 May;18(5):1041.

PMID:
12835720
18.

ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.

Giona F, Testi AM, Rondelli R, Amadori S, Arcese W, Meloni G, Moleti ML, Ceci A, Pillon M, Madon E, Comis M, Pession A, Mandelli F.

Br J Haematol. 1997 Dec;99(3):671-7.

PMID:
9401083
19.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
20.

Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.

Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, Ahn HS.

Blood. 2007 Jan 15;109(2):471-7. Epub 2006 Sep 21.

Supplemental Content

Support Center